



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/589,975	07/11/2007	Isabelle Hansenne	293093US0PCT	2369
22850 7590 10/13/2010 OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, L.L.P. 1940 DUKE STREET ALEXANDRIA, VA 22314				
EXAMINER KISHORE, GOLLAMUDI S				
ART UNIT		PAPER NUMBER		
1612				
NOTIFICATION DATE		DELIVERY MODE		
10/13/2010		ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com
oblonpat@oblon.com
jgardner@oblon.com

Office Action Summary

Application No.

10/589,975

Applicant(s)

HANSENNE ET AL.

Examiner

GOLLAMUDI S. KISHORE

Art Unit

1612

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-20 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-20 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☒ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/22)
Paper No(s)/Mail Date 12-8-06
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date ____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: ____

DETAILED ACTION

Claims included in the prosecution are 1-20.

Claim Rejections - 35 USC § 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 1-8, 11-14 and 17-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Harding (US 5,705,144) by itself or in combination with Reynolds (5,431,911).

Harding et al. teaches a composition to lighten the skin and the repair of photo-damaged skin comprising a dioic acid having the general structure of $\text{COOH}-(\text{CaHb})-\text{COOH}$, where a is an integer from 6 to 20 and b is an integer from 8 to 40 (see abstract and col. 2, lines 10-26). The compound 8-hexadecene-1, 16-dicarboxylic acid is a species of the dioc acid of Harding et al. where a is 16 and b is 30. The compositions further contain a hydroxy acid. According to Harding, the composition is topically applied to human skin to repair photo-damaged skin and to prevent photo-damage to skin due to exposure to sunlight, to reduce skin blotchiness and mottling due to hyperpigmentation, to improve skin texture with reductions in fine wrinkling and to treat actinic damage to all epidermal cells (col. 11, lines 31-42). Although Harding does not teach as

to how long the composition has to be applied, since the composition is for topical application, it would have been obvious to one of ordinary skill in the art to keep the formulation on the skin to achieve the desired purpose. Rinsing the composition off of the skin is within the skill of the art of cosmetics since cosmetic compositions such as sunscreens are rinsed routinely. Such a skill is also evident from Reynolds which teaches the application of the skin compositions to protect it against dryness and wrinkles for 20 minutes and removing the composition by a cold water rinse (abstract, col. 1, lines 55-62; col. 3, lines 49-66). The criticality of the amounts of 8-hexadecene-1, 16 dicarboxylic acid and the beta-hydroxy acid is unclear to the examiner since the amounts depend upon the condition to be treated and thus, a manipulatable parameter.

3. Claims 8-11 and 14-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Harding (US 5,705,144) by itself or in combination with Reynolds (5,431,911) as set forth above, further in view of Jones (US 2004/0126352).

The teachings of Harding and Reynolds have been discussed above. Harding does not specify that the hydroxy acid to be a salicylic acid.

Jones while disclosing compositions for treating facial wrinkles teaches that hydroxy acids such as octanoylsalicylic acid and octylsalicylic acids are anti-wrinkle agents. The composition is applied for a period of time sufficient to improve the aesthetic appearance of skin. (0002, 0029 and 0042 and claim 3).

To include a salicylic acid derivative such as octanoylsalicylic acid in Harding with the expectation of obtaining at least an additive effect would have been obvious to one of ordinary skill in the art since Jones teaches that salicylic acids are anti-wrinkle

agents. The criticality of the amounts of 8-hexadecene-1, 16 dicarboxylic acid and the beta-hydroxy acid is unclear to the examiner since the amounts depend upon the condition to be treated and thus, a manipulatable parameter.

4. Claims 1-7 and 12-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Research disclosure # 477 in combination with Internet article 002301860(both are of record) and Reynolds (5,431,911).

The research disclosure teaches that Arlatone Dioic DCA works through PPAR gamma ligands and this compound is for anti-aging, skin lightening, age spot reduction and acne (page 3 of the article). The amounts taught by the disclosure are 0.0001 to 10 %.

The internet article discloses that the product of Arlatone Dioic DCA is available in the market and can be used for day and night creams and skin treatment systems (Table 2).

These references however, do not teach the leaving the composition on the skin for a period of 5 minutes to 6 hours and rinsing the composition.

Reynolds teaches the application of the skin compositions to protect it against dryness and wrinkles for 20 minutes and removing the composition by a cold water rinse (abstract, col. 1, lines 55-62; col. 3, lines 49-66).

To leave the composition containing Arlatone Dioic DCA on the skin for sufficient period and then rinse it off to treat skin blemishes would have been obvious to one of ordinary skill in the art since the Internet article teaches that this compound can be

formulated in day and night creams and Reynolds teaches that such a method of removing wrinkles is routinely practiced in the art.

5. Claims 8-11 and 14-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Research disclosure # 477 in combination with Internet article 002301860(both are of record) and Reynolds (5,431,911) as set forth above, further in view of Jones (US2004/0126352).

The teachings of Research disclosure, Internet article and Reynolds have been discussed above. What is lacking in these references is the use of salicylic acid.

Jones while disclosing compositions for treating facial wrinkles teaches that hydroxy acids such as octanoylsalicylic acid and octylsalicylic acids are anti-wrinkle agents. The composition is applied for a period of time sufficient to improve the aesthetic appearance of skin. (0002, 0029 and 0042 and claim 3).

To include a salicylic acid derivative such as octanoylsalicylic acid in compositions containing Arlatone Dioic DCA with the expectation of obtaining at least an additive effect would have been obvious to one of ordinary skill in the art since Jones teaches that salicylic acids are anti-wrinkle agents. The criticality of the amounts of 8-hexadecene-1, 16 dicarboxylic acid and the beta-hydroxy acid is unclear to the examiner since the amounts depend upon the condition to be treated and thus, a manipulatable parameter.

6. Claims 1-9, 11-15 and 17-19 are rejected under 35 U.S.C. 103(a) as being unpatentable over DE 101 50 734 (English equivalent, US 2005/0008665) of record by itself or in combination with Reynolds (5,431,911).

DE teaches cosmetic compositions for the treatment of skin changes such as unwanted pigmentation, hyper pigmentation, local hyper pigmentation and faulty pigmentation by application of a composition containing 8-hexadecene-1, 16 dicarboxylic acid. The amount to be applied is from 0.001 % to 10 % (Abstract; 0002-0003; 0006; 0064; 0074 of English equivalent). The compositions further contain a salicylate (0088). Although DE does not teach as to how long the composition has to be applied, since the composition is for topical application, it would have been obvious to one of ordinary skill in the art to keep the formulation on the skin to achieve the desired purpose. Rinsing the composition off of the skin is within the skill of the art of cosmetics since cosmetic compositions such as sunscreens are rinsed routinely. Such a skill is also evident from Reynolds which teaches the application of the skin compositions to protect it against dryness and wrinkles for 20 minutes and removing the composition by a cold water rinse (abstract, col. 1, lines 55-62; col. 3, lines 49-66). The criticality of the amounts of 8-hexadecene-1, 16 dicarboxylic acid and the beta-hydroxy acid is unclear to the examiner since the amounts depend upon the condition to be treated and thus, a manipulatable parameter.

7. Claims 8-11 and 14-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over DE 101 50 734 (English equivalent, US 2005/0008665) by itself or in

combination with Reynolds (5,431,911) as set forth above, further in view of Jones (US2004/0126352).

The teachings of DE and Reynolds have been discussed above.

Jones while disclosing compositions for treating facial wrinkles teaches that hydroxy acids such as octanoylsalicylic acid and octylsalicylic acids are anti-wrinkle agents. The composition is applied for a period of time sufficient to improve the aesthetic appearance of skin. (0002, 0029 and 0042 and claim 3).

To include a salicylic acid derivative such as octanoylsalicylic acid in Harding with the expectation of obtaining at least an additive effect would have been obvious to one of ordinary skill in the art since Jones teaches that salicylic acids are anti-wrinkle agents. The criticality of the amounts of 8-hexadecene-1, 16 dicarboxylic acid and the beta-hydroxy acid is unclear to the examiner since the amounts depend upon the condition to be treated and thus, a manipulatable parameter.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to GOLLAMUDI S. KISHORE whose telephone number is (571)272-0598. The examiner can normally be reached on 6:30 AM- 4 PM, alternate Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Krass Frederick can be reached on (571) 272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Gollamudi S Kishore/
Primary Examiner, Art Unit 1612

GSK